IL-1 in aging and pathologies of hematopoietic stem cells
Open Access
- 25 July 2024
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 144 (4) , 368-377
Abstract
Defense-oriented inflammatory reactivity supports survival at younger age but might contribute to health impairments in modern, aging societies. The interleukin-1 (IL-1) cytokines are highly conserved and regulated, pleiotropic mediators of inflammation, essential to respond adequately to infection and tissue damage but also with potential host damaging effects when left unresolved. In this review, we discuss how continuous low-level IL-1 signaling contributes to aging-associated hematopoietic stem and progenitor cell (HSPC) functional impairments and how this inflammatory selective pressure acts as a driver of more profound hematological alterations, such as clonal hematopoiesis of indeterminate potential, and to overt HSPC diseases, like myeloproliferative and myelodysplastic neoplasia as well as acute myeloid leukemia. Based on this, we outline how IL-1 pathway inhibition might be used to prevent or treat inflammaging-associated HSPC pathologies.Keywords
This publication has 117 references indexed in Scilit:
- TET2-Driven Clonal Hematopoiesis and Response to CanakinumabJAMA Cardiology, 2022
- Interleukin-1β as emerging therapeutic target in hematological malignancies and potentially in their complicationsBlood Reviews, 2017
- Secretion of IL‐1β from imatinib‐resistant chronic myeloid leukemia cells contributes to BCR–ABL mutation‐independent imatinib resistanceFEBS Letters, 2016
- Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic SyndromeCancer Cell, 2013
- Plasma cytokines in polycythemia vera: Phenotypic correlates, prognostic relevance, and comparison with myelofibrosisAmerican Journal of Hematology, 2012
- Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous LeukemiaCancer Cell, 2012
- Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid TransformationCancer Cell, 2011
- Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor CellsCancer Cell, 2010
- Hematopoiesis: An Evolving Paradigm for Stem Cell BiologyCell, 2008
- Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisCancer Cell, 2005